No article text was recorded for this version.
synthetic lethality
Version 1 of 146 papers75 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
- Blog: SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma
- Blog: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
- Blog: Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistance
- Blog: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
- Blog: FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration
- Blog: The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient
- Blog: Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
- Blog: Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
- Blog: Genomic features of renal cell carcinoma with venous tumor thrombus
- Blog: Small intestinal neuroendocrine tumors lack early genomic drivers, acquire DNA repair defects and harbor hallmarks of low REST expression
- Blog: Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
- Blog: BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
- Blog: Identification of the KIF18A alpha-4 helix as a therapeutic target for chromosomally unstable tumor cells
- Blog: Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
- Blog: Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma
- Blog: Integrative genomic and transcriptomic analysis of leiomyosarcoma
- Blog: Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions
- Blog: Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair
- Blog: A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia
- Blog: Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer
- Blog: A Genetic Screen for High Copy Number Suppressors of the Synthetic Lethality Between<i>elg1Δ</i>and<i>srs2Δ</i>in Yeast
- Blog: Role of the Rab GTP-Binding Protein Ypt3 in the Fission Yeast Exocytic Pathway and Its Connection to Calcineurin Function
- Blog: AURKA emerges as a vulnerable target for KEAP1-deficient non-small cell lung cancer by activation of asparagine synthesis
- Blog: Divergent mutational processes distinguish hypoxic and normoxic tumours
- Blog: Abrogation of KLF5 sensitizes &lt;italic&gt;BRCA1&lt;/italic&gt;-proficient pancreatic cancer to PARP inhibition
- Blog: Chronic Loss of STAG2 Leads to Altered Chromatin Structure Contributing to DE-Regulated Transcription in AML.
- Blog: Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer
- Blog: Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment
- Blog: Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling
- Blog: A rare case of TFEB/6p21/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review
- Blog: Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)
- Blog: Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients
- Blog: Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma
- Blog: Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens
- Blog: KR4SL: knowledge graph reasoning for explainable prediction of synthetic lethality
- Blog: Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through non-homologous end joining
- Blog: SynLethDB 2.0: A web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery
- Blog: Small‐Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases
- Blog: Integrative genomic analysis of salivary duct carcinoma
- Blog: SL-Miner: a web server for mining evidence and prioritization of cancer-specific synthetic lethality
- Blog: Targeting HSPA1A in ARID2-deficient lung adenocarcinoma
- Blog: A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation
- Blog: Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
- Blog: BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges
- Blog: The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_synthetic_lethality_25d8776a,
title = {synthetic lethality},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/synthetic-lethality/rdr_25d8776aabf0405e95eebc9f76b8e824},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_synthetic_lethality_25d8776a_v1,
title = {synthetic lethality},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/synthetic-lethality/rdr_25d8776aabf0405e95eebc9f76b8e824/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}